Mohler JL - Search Results

1

Lipid degradation promotes prostate cancer cell survival.

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, Mohler JL, Clarke N, Swinnen JV, Keun HC, Rekvig OP, Mills IG. Itkonen HM, et al. Among authors: mohler jl. Oncotarget. 2017 Jun 13;8(24):38264-38275. doi: 10.18632/oncotarget.16123. Oncotarget. 2017. PMID: 28415728 Free PMC article.

2

Hypoxia increases androgen receptor activity in prostate cancer cells.

Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, Hidalgo AA, Ip C, Park EM, Yoon SY, Park YM. Park SY, et al. Among authors: mohler jl. Cancer Res. 2006 May 15;66(10):5121-9. doi: 10.1158/0008-5472.CAN-05-1341. Cancer Res. 2006. PMID: 16707435

3

A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Mohler JL. Mohler JL. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):357-72. doi: 10.1016/j.beem.2008.01.009. Best Pract Res Clin Endocrinol Metab. 2008. PMID: 18471792 Free PMC article. Review.

4

The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction.

Cheng J, Wu Y, Mohler JL, Ip C. Cheng J, et al. Among authors: mohler jl. Cancer Biol Ther. 2010 Jun 15;9(12):1033-42. doi: 10.4161/cbt.9.12.11876. Epub 2010 Jun 24. Cancer Biol Ther. 2010. PMID: 20404538 Free PMC article.

5

Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.

Wu Y, Chhipa RR, Cheng J, Zhang H, Mohler JL, Ip C. Wu Y, et al. Among authors: mohler jl. Anticancer Res. 2010 Oct;30(10):3895-901. Anticancer Res. 2010. PMID: 21036700 Free PMC article.

6

Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.

Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM. Mohler JL, et al. Cancer Res. 2011 Feb 15;71(4):1486-96. doi: 10.1158/0008-5472.CAN-10-1343. Epub 2011 Feb 8. Cancer Res. 2011. PMID: 21303972 Free PMC article.

7

Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.

Titus MA, Zeithaml B, Kantor B, Li X, Haack K, Moore DT, Wilson EM, Mohler JL, Kafri T. Titus MA, et al. Among authors: mohler jl. PLoS One. 2012;7(1):e30192. doi: 10.1371/journal.pone.0030192. Epub 2012 Jan 17. PLoS One. 2012. PMID: 22272301 Free PMC article.

8

Ten years of progress in prostate cancer.

Mohler JL. Mohler JL. J Natl Compr Canc Netw. 2012 Feb;10(2):136-40. doi: 10.6004/jnccn.2012.0016. J Natl Compr Canc Netw. 2012. PMID: 22308512 No abstract available.

9

RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.

Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, Sebo TJ, Tindall DJ, Heemers HV. Schmidt LJ, et al. Among authors: mohler jl. Mol Endocrinol. 2012 May;26(5):716-35. doi: 10.1210/me.2011-1130. Epub 2012 Mar 28. Mol Endocrinol. 2012. PMID: 22456196 Free PMC article.

10

Biology of castration-recurrent prostate cancer.

Azzouni F, Mohler J. Azzouni F, et al. Urol Clin North Am. 2012 Nov;39(4):435-52. doi: 10.1016/j.ucl.2012.07.002. Epub 2012 Aug 27. Urol Clin North Am. 2012. PMID: 23084522 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

358 results

Search Page